Literature DB >> 1311275

Role of hepatitis C virus in acute non-A, non-B hepatitis in Greece: a 5-year prospective study.

N C Tassopoulos1, A Hatzakis, I Delladetsima, M G Koutelou, A Todoulos, V Miriagou.   

Abstract

The prevalence of hepatitis C virus (HCV) infection in 182 prospectively followed adult patients (110 males, 72 females) with acute non-A, non-B hepatitis and its correlation with progression to chronic hepatitis were studied. These patients were followed for a mean of 24.7 +/- 13.1 (range, 6-57) months. By using a specific enzyme immunoassay for the detection of antibodies against C100-3 polypeptide of HCV, 96 (52.7%) were found antibody positive. HCV was implicated in 64/89 (71.9%) of the cases with classical parenteral exposure but only in 18/64 (28.1%) of the community-acquired cases. Progression to chronic hepatitis was observed more frequently in antibody-positive than in antibody-negative cases (60/96 or 62.5% vs. 27/86 or 31.4%, P = 0.00002). Progression was also observed more often in males than in females (66/112 or 58.9% vs. 21/70 or 30.0% P = 0.0001), both in the antibody positive (48/68 or 70.6% vs. 12/28 or 42.9%, P = 0.01) and in the antibody negative (18/44 or 40.9% vs. 9/42 or 21.4%, P = 0.043) cases. These data indicate that (a) acute hepatitis due to HCV is characterized by a high rate of chronicity, especially in males, and (b) a non-A, non-B, non-C agent or a different strain of HCV may be responsible for the majority of the community-acquired cases of non-A, non-B hepatitis in Greece.

Entities:  

Mesh:

Year:  1992        PMID: 1311275     DOI: 10.1016/0016-5085(92)90184-z

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Treatment of acute non-A, non-B hepatitis with interferon alpha-2b.

Authors:  N C Tassopoulos; M Koutelou; G Papatheodoridis; H Polychronaki; T Giannikakis; M Paraloglou-Ioannides; A Hatzakis
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Interferon as treatment for acute hepatitis C. A meta-analysis.

Authors:  C Cammà; P Almasio; A Craxì
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 3.  Patterns of progression: unpredictability and risk of decompensated cirrhosis.

Authors:  N C Tassopoulos
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Acute non-A, non-B hepatitis in Italy: a 16-year prospective epidemiological study. The possible role of hepatitis C virus.

Authors:  F Bortolotti; C Crivellaro; M Carretta; A Tagger; M Ribero; A Bertolini; E Barbierato; F Noventa; P Cadrobbi
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

5.  Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor.

Authors:  M Matsumoto; T Y Hsieh; N Zhu; T VanArsdale; S B Hwang; K S Jeng; A E Gorbalenya; S Y Lo; J H Ou; C F Ware; M M Lai
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 6.  Hepatitis G virus: is it a hepatitis virus?

Authors:  R C Cheung; E B Keeffe; H B Greenberg
Journal:  West J Med       Date:  1997-07

7.  Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

Authors:  N C Tassopoulos; M G Koutelou; G Papatheodoridis; H Polychronaki; I Delladetsima; T Giannikakis; A Todoulos; A Toliopoulos; A Hatzakis
Journal:  Gut       Date:  1993       Impact factor: 23.059

8.  Epidemiological, clinical and biological characteristics of acute non-A, non-B hepatitis with and without hepatitis C virus infection.

Authors:  C A Navascués; M Rodríguez; N G Sotorrío; P Leiva; A Martínez; R Pérez; J de la Vega; L Rodrigo
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.